This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Acceleron Pharma Inc. [XLRN], a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics to improve the lives of patients with cancer and rare diseases, will visit the NASDAQ MarketSite in Times Square.
Acceleron completed a successful IPO in September 2013 which raised net proceeds of approximately $97M.
Acceleron has three protein therapeutics being studied in 12 ongoing phase 2 clinical trials.
Acceleron is developing two of its clinical programs (sotatercept and ACE-536) in a joint collaboration with partner Celgene [CELG] for the treatment of anemia in patients with rare blood diseases.
Acceleron expects to present interim clinical results from its ongoing phase 2 clinical trial of sotatercept in patients with beta-thalassemia in early December at the American Society of Hematology's Annual Meeting.
Acceleron will announce its third quarter 2013 financial results on Wednesday, November 6 th at 9:00 AM.
In honor of the occasion,
John Knopf, CEO will ring the Closing Bell. Dr. Knopf will be joined by the Acceleron management team, employees, colleagues and friends to celebrate the occasion.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Tuesday, November 5, 2013 – 3:45 p.m. to 4:00 p.m. ET
Contact: Maureen L. Suda (Media) Suda Communications LLC (585) 387-9248
NASDAQ MarketSite: Christine Barna (646) 441-5310
Christine.Barna@nasdaqomx.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Acceleron Pharma Inc. [XLRN]:
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.